38 peptide profiles. Every claim backed by published, peer-reviewed research. Every source auditable. Built by the licensed distributor that actually supplies them — compliantly, with full chain of custody.
iRemedy is a licensed pharmaceutical distributor supplying compounded peptides to healthcare professionals across all 50 states. Our Peptide Academy provides evidence-graded clinical profiles — each rigorously sourced, transparently cited, and written to serve prescribers and procurement professionals who require accuracy over hype. Every peptide we supply comes with complete chain of custody documentation, COA, and country-of-origin disclosure.
Regulatory-approved indication with substantial Phase III RCT evidence. Highest confidence tier. Includes A+ for multi-trial concordance and landmark outcomes data.
Human clinical trial data — Phase I/II completed, positive signals, methodology sound. Not yet FDA-approved or awaiting confirmatory trial. B+ denotes robust Phase II evidence.
Early-phase human data or strong translational evidence from animal models. Mechanism plausible; clinical generalizability remains limited. C+ indicates early-phase human trials exist.
Animal models or in vitro data only. No completed human trials. Mechanism of interest, but clinical applicability unproven. D+ indicates novel mechanistic plausibility.